Acquired Company
Forbion European Acquisition Corp. completed the business combination with enGene on 11/1/2023, and enGene Holdings Inc. began trading under the symbol ENGN.
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. enGene Holdings Inc. is based in Montreal, Canada. Show more
4868 Rue Levy, Montreal, QC, H4R 2P1, Canada
Start AI Chat
Market Cap
647.7M
52 Wk Range
$2.65 - $12.25
Previous Close
$9.67
Open
$9.79
Volume
329,069
Day Range
$9.58 - $10.10
Enterprise Value
204.5M
Cash
193.7M
Avg Qtr Burn
-24.96M
Insider Ownership
0.09%
Institutional Own.
97.73%
Qtr Updated
10/31/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Detalimogene (EG-70) Details Non-Muscle Invasive Bladder Cancer (NMIBC) | Phase 2 Data readout |